Drug resistant hypertension – no simple way out

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Nephrology

Background:

• Resistant hypertension is a significant global health challenge.
• Renal denervation is an emerging therapy for difficult-to-treat hypertension.
• The Symplicity-III trial (HTN-3) aimed to evaluate renal denervation's efficacy.

Purpose of the Study:

• To review clinical and experimental studies on renal denervation.
• To identify reasons for inconsistent outcomes in renal denervation research.
• To analyze the basic science supporting renal denervation and clinical trial designs.

Main Methods:

• Review of published clinical trials and experimental studies on renal denervation.
• Analysis of the Symplicity-III (HTN-3) trial data.
• Examination of the scientific rationale and methodological aspects of renal denervation studies.

Main Results:

• The Symplicity-III trial did not demonstrate a significant blood pressure reduction 6 months post-renal artery denervation compared to controls.
• Inconsistent results exist across various renal denervation studies.
• Basic science and clinical trial design factors may influence outcomes.

Conclusions:

• Current evidence from the HTN-3 trial suggests renal denervation may not be effective for resistant hypertension.
• Further investigation into the underlying mechanisms and optimal trial design for renal denervation is warranted.
• Understanding the variability in renal denervation outcomes is crucial for future therapeutic development.